![File:Development of better monoclonal antibodies for human therapy and their nomenclature.svg - Wikimedia Commons File:Development of better monoclonal antibodies for human therapy and their nomenclature.svg - Wikimedia Commons](https://upload.wikimedia.org/wikipedia/commons/thumb/a/af/Development_of_better_monoclonal_antibodies_for_human_therapy_and_their_nomenclature.svg/2560px-Development_of_better_monoclonal_antibodies_for_human_therapy_and_their_nomenclature.svg.png)
File:Development of better monoclonal antibodies for human therapy and their nomenclature.svg - Wikimedia Commons
![Genentech pays doctors to prescribe its newer more expensive drug, which costs $2,000/dose vs. older, cheaper, equally-effective drug Avastin ($50/dose). Cost to taxpayers: $1 B-billion/A YEAR : r/news Genentech pays doctors to prescribe its newer more expensive drug, which costs $2,000/dose vs. older, cheaper, equally-effective drug Avastin ($50/dose). Cost to taxpayers: $1 B-billion/A YEAR : r/news](https://external-preview.redd.it/LD7Ry0_X2CUCWdjHenPM9s3pKDgAeatdf1e-mYn04XM.jpg?auto=webp&s=a41b78e45df098fc0cf728c1575b5e87ade542a2)
Genentech pays doctors to prescribe its newer more expensive drug, which costs $2,000/dose vs. older, cheaper, equally-effective drug Avastin ($50/dose). Cost to taxpayers: $1 B-billion/A YEAR : r/news
![Bevacizumab-awwb becomes first biosimilar approved for cancer treatment | MDedge Hematology and Oncology Bevacizumab-awwb becomes first biosimilar approved for cancer treatment | MDedge Hematology and Oncology](https://cdn.mdedge.com/files/s3fs-public/Image/April-2018/218_de%20Lartigue_CT1_F_web.png)